Covid 19 Research using Clinical Trials (Home Page)
(Standard of Care) SoCWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
|
Name (Synonyms) |
Correlation |
drug67 | Assessment of Dietary Changes in Adults in the Quarantine Wiki | 1.00 |
drug691 | Remdesivir Wiki | 0.30 |
drug360 | Hydroxychloroquine Wiki | 0.13 |
Correlated MeSH Terms (5)
|
Name (Synonyms) |
Correlation |
D055371 | Acute Lung Injury NIH | 0.16 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.15 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.13 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.07 |
D018352 | Coronavirus Infections NIH | 0.06 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a
multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy
of hydroxychloroquine, remdesivir and standard of care in hospitalized adult patients
diagnosed with COVID-19. This trial will follow the core WHO protocol but has additional
efficacy, safety and explorative endpoints.
Primary Outcomes
Description: All cause in-hospital mortality
Measure: In-hospital mortality
Time: 3 weeks
Secondary Outcomes
Measure: Occurrence and duration of mechanical ventilation Time: 3 weeks
Measure: Occurrence and duration of intensive care unit (ICU) treatment Time: 3 weeks
Measure: Duration of hospital admittance Time: 1 month
Measure: 28 Day mortality Time: 3 weeks
Measure: Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen Time: 3 weeks
Measure: Occurrence of co-infections Time: 3 weeks
Measure: Occurrence of organ dysfunction Time: 3 months
Other Outcomes
Measure: Inflammatory and anti-inflammatory mediators as assessed in serum and plasma Time: Throughout hospitalization
Measure: Markers of extracellular matrix remodeling Time: Throughout hospitalization and 3 months after remission
Measure: Markers of endothelial activation Time: Throughout hospitalization
Measure: Markers of platelet activation Time: Throughout hospitalization
No related HPO nodes (Using clinical trials)